Boswellia

• Osteoarthritis pain, stiffness, and joint function (short-term, best-supported)
• Rheumatoid arthritis, as an adjunct
• Ulcerative colitis, as an adjunct (small older trials)
• Crohn's disease, as an adjunct (small older trials)
• Asthma, as an adjunct (one small 1998 trial)
• General anti-inflammatory daily use

Boswellia (Indian frankincense) is the resin exudate of the Boswellia genus trees, predominantly Boswellia serrata (Indian frankincense, the principal commercial source) and Boswellia carteri (Arabian frankincense, substantial historical religious and aromatic use), with substantial supplementary species (Boswellia sacra, Boswellia papyrifera, Boswellia rivae). The substantial pharmacology centers on a family of pentacyclic triterpenoids called boswellic acids, particularly the standardized targets β-boswellic acid, 11-keto-β-boswellic acid (KBA), and acetyl-11-keto-β-boswellic acid (AKBA, the most pharmacologically active and commercially standardized constituent). The substantial extract chemistry is complex, total boswellic acids comprise roughly 30-65% of the resin; AKBA typically 3-5% of total boswellic acids in unmodified extracts but standardized to 20-30% in concentrated commercial products (5-Loxin from Sabinsa standardized to 30% AKBA being the substantial commercial benchmark). The pharmacological mechanism profile centers on substantial 5-lipoxygenase (5-LOX) inhibition, a substantially distinct anti-inflammatory mechanism from the COX (cyclooxygenase) inhibition of NSAIDs and aspirin. The 5-LOX pathway produces leukotrienes from arachidonic acid; leukotrienes are potent inflammatory mediators particularly involved in asthma, allergic inflammation, inflammatory bowel disease, and joint inflammation. Boswellic acids (predominantly AKBA) inhibit 5-LOX through a substantially specific allosteric mechanism, substantially distinct from the NSAID COX inhibition and distinct from the leukotriene receptor antagonists (montelukast). The substantial mechanistic distinctness provides reasonable rationale for combination with NSAID therapy, substantial mechanistically complementary anti-inflammatory framework. Additional mechanisms include modulation of cathepsin G activity, modulation of complement system (particularly C3 convertase inhibition), modulation of NF-κB signaling (substantial overlap with curcumin mechanism), and modest matrix metalloproteinase inhibition relevant to cartilage degradation. The substantial Ayurvedic heritage is foundational, Boswellia serrata resin (Salai guggal in Sanskrit) has substantial documented use across multiple millennia in traditional Indian medicine for arthritis, asthma, inflammatory conditions, and digestive disorders. The substantial heritage extends beyond Ayurvedic medicine to substantial traditional Middle Eastern medicine (Boswellia sacra particularly for ceremonial and medicinal use), substantial historical religious use (frankincense in Christianity, Judaism, Islam, the substantial cultural and religious heritage), and substantial historical trade significance (the Frankincense Trail across the Arabian peninsula was substantial economic infrastructure for substantial periods). Pliny the Elder, Hippocrates, and various other classical writers documented substantial medicinal use; substantial modern pharmacological research has substantially confirmed underlying anti-inflammatory mechanisms. The substantial commercial development framework centers on AKBA standardization. 5-Loxin (Sabinsa, standardized to 30% AKBA) was the substantial foundational standardized commercial product, substantial 2008 Sengupta Arthritis Res Ther 5-Loxin osteoarthritis RCT provided foundational clinical evidence for the standardized formulation framework. Aflapin (Sabinsa, 20% AKBA enhanced with polysaccharide carrier providing approximately 25% improved bioavailability) represents substantial subsequent commercial development. Apres Flex (Laila Nutraceuticals, water-soluble AKBA) addresses the substantial water-solubility limitation of native boswellic acids. BosPure (PLT Health Solutions), Boswellin Super (Sabinsa - 70% organic acids of which 10% AKBA), and various other commercial products represent substantial market segmentation. The substantial M-07 Form-Factor flag content, different boswellia formulations are not pharmacologically equivalent, and AKBA standardization matters substantially for clinical outcomes. The substantial clinical evidence base centers predominantly on osteoarthritis and inflammatory joint conditions. Sengupta 2008 Arthritis Res Ther provided foundational evidence for 5-Loxin in osteoarthritis. Kimmatkar 2003 Phytomedicine provided earlier OA evidence. Vishal 2011 demonstrated knee OA improvement comparable to celecoxib at modest doses. Bannuru 2018 meta-analysis confirmed substantial OA evidence base. Inflammatory bowel disease evidence includes Madisch 2007 ulcerative colitis (boswellia extract H15 comparable to mesalamine in maintenance of UC remission) and Gerhardt 2001 Crohn's evidence. Asthma evidence includes Gupta 1998 Eur J Med Res. The substantial overall evidence base is more substantial than substantial broader supplement category but more modest than substantial pharmaceutical anti-inflammatory framework, reasonable adjunctive evidence base across inflammatory conditions. The substantial safety profile is generally favorable. Substantial Ayurvedic heritage and modern clinical experience suggest substantial tolerability at standard supplementation doses. Mild GI effects (nausea, mild abdominal discomfort, occasional loose stools) most common; typically resolve with adjustment. Substantial drug interaction profile is more modest than substantial supplement category equivalents, modest anticoagulant interaction (theoretical antiplatelet effects), modest CYP450 interaction (substantially less than curcumin). The substantial pregnancy safety data is limited; traditional Ayurvedic practitioners have substantial historical use frameworks but modern therapeutic supplementation generally avoided during pregnancy without specialist coordination.

Boswellia therapeutic dosing varies substantially by formulation and clinical application. 5-Loxin (Sabinsa standardized 30% AKBA): 100-250mg daily providing substantial AKBA dose; substantial Sengupta 2008 OA evidence base. Aflapin (Sabinsa AKBA + polysaccharide carrier enhanced bioavailability): 100-200mg daily; substantial Vishal 2011 OA evidence base with enhanced bioavailability framework. Apres Flex (Laila Nutraceuticals water-soluble AKBA): 100-300mg daily; reasonable bioavailability enhancement framework. Standard Boswellia serrata 60-65% boswellic acids: 300-800mg daily; conventional standardized extract framework. H15 extract (substantial European commercial heritage including Madisch 2007 UC evidence): 1200mg three times daily for inflammatory bowel disease applications. Combination curcumin-boswellia products (Curamin, Curamed): per combination product specification. Take with meals, boswellic acids are lipophilic and substantial fat content modestly enhances absorption. Treatment durations matter substantially, anti-inflammatory effects typically develop over 4-12 weeks of consistent supplementation; acute effects modest. AKBA-standardized formulations (5-Loxin, Aflapin) generally preferred over conventional boswellia extracts for clinical applications. Drug interaction profile is more modest than substantial supplement category equivalents, modest theoretical antiplatelet effects warrant routine anticoagulation coordination; modest CYP450 interaction; modest glucose-modulating effects warrant routine diabetes coordination. Pregnancy and lactation: limited modern therapeutic supplementation safety data; substantial Ayurvedic heritage includes pregnancy use frameworks; modern therapeutic supplementation generally avoided without specialist coordination. Pediatric use: limited modern therapeutic supplementation framework; specialist coordination essential. Surgical patients: discontinue 1 week pre-operatively given modest antiplatelet effects. The substantial Ayurvedic heritage framework provides reasonable supplementation framework for users prioritizing traditional medicine approach; modern AKBA-standardized formulations provide reasonable supplementation framework for users prioritizing standardized clinical evidence approach. The substantial mechanistic distinctness from NSAID COX inhibition provides reasonable framework for combination supplementation with NSAID therapy, substantial dual-pathway anti-inflammatory approach.

5-Loxin standard dose

100-250mg/day (30% AKBA)

Aflapin standard dose

100-200mg/day (enhanced bioavailability)

Apres Flex

100-300mg/day (water-soluble AKBA)

Standard 60-65% extract

300-800mg/day

H15 extract for IBD

1200mg three times daily

Take with

Meals containing fat (lipophilic)

Treatment duration for chronic effects

4-12+ weeks

AKBA standardization

30% (5-Loxin) most substantial commercial benchmark

• 5-Loxin (Sabinsa standardized 30% AKBA)

  Rating: gold

  The foundational AKBA-standardized commercial product, Boswellia serrata extract standardized to 30% AKBA. Substantial Sengupta 2008 OA RCT clinical evidence base. Substantial commercial heritage through Sabinsa (Muhammed Majeed company). Typical dosing: 100-250mg daily providing substantial AKBA dose. Among the substantial bioavailability-enhanced commercial formulations.

• Aflapin (Sabinsa AKBA + polysaccharide carrier)

  Rating: gold

  Enhanced bioavailability AKBA formulation with polysaccharide carrier providing approximately 25% improved bioavailability versus 5-Loxin. Substantial Vishal 2011 OA evidence base demonstrating substantial pain reduction at lower doses through enhanced bioavailability. Substantial Sabinsa commercial framework.

• Apres Flex (Laila Nutraceuticals water-soluble AKBA)

  Rating: good

  Water-soluble AKBA formulation addressing substantial water-solubility limitation of native boswellic acids. Substantial commercial framework through Laila Nutraceuticals (Indian botanical company). Reasonable bioavailability enhancement approach.

• Boswellin Super (Sabinsa 70% organic acids)

  Rating: good

  Substantial Boswellia serrata extract standardized to 70% organic acids (boswellic acids) including approximately 10% AKBA. Provides substantial broad-spectrum boswellic acid supplementation. Substantial commercial framework through Sabinsa.

• Standard Boswellia Serrata 60-65% Boswellic Acids

  Rating: good

  Conventional standardized Boswellia serrata extract, substantial commercial framework across multiple manufacturers. AKBA content typically not specified or substantially modest. Generally less expensive than AKBA-standardized formulations; substantially less clinical evidence than 5-Loxin or Aflapin frameworks.

• BosPure (PLT Health Solutions)

  Rating: good

  Substantial Boswellia serrata extract from PLT Health Solutions with substantial commercial positioning. Various standardization frameworks available.

• Combination Curcumin + Boswellia (Curamin, Curamed, others)

  Rating: gold

  Substantial mechanistically complementary combination, curcumin acts through NF-κB and COX-2; boswellia acts through 5-LOX. Substantial dual-pathway anti-inflammatory framework. Substantial commercial products including Curamin from Terry Naturally, Curamed combinations, and substantial broader category. Reasonable comprehensive anti-inflammatory framework.

• Boswellia Resin (Traditional Form)

  Rating: good

  Raw or minimally processed Boswellia serrata resin, substantial traditional Ayurvedic and Middle Eastern medicinal heritage. Substantially less concentrated than standardized extracts; substantial broader phytochemical complement. Substantial historical and cultural use framework.

• Boswellia Essential Oil (Frankincense Oil)

  Rating: caution

  Steam-distilled Boswellia serrata, sacra, or carteri essential oil, substantial aromatherapy and cosmetic use frameworks. Substantial volatile compound profile (monoterpenes); substantially distinct pharmacology from boswellic acid oral supplementation. Not generally used for anti-inflammatory therapeutic supplementation.

• Osteoarthritis (knee, hip, hand) joint pain

  Strength of evidence for this group: modest

  Substantial OA clinical evidence base, Sengupta 2008 5-Loxin, Kimmatkar 2003, Vishal 2011 Aflapin, Bannuru 2018 meta-analysis. Reasonable adjunct or alternative to NSAIDs; modest effect sizes (substantial for some patients). AKBA-standardized formulations (5-Loxin, Aflapin) preferred over conventional boswellia extracts.

• Rheumatoid arthritis (adjunctive)

  Strength of evidence for this group: cautious

  Sander 1998 pilot evidence and substantial mechanistic rationale; substantially less developed RA clinical evidence than OA. Reasonable adjunct to established RA therapy under rheumatology coordination. Not substitute for DMARDs, biologics, or other established RA treatment.

• Inflammatory bowel disease (UC, Crohn's) adjunctive

  Strength of evidence for this group: cautious

  Madisch 2007 ulcerative colitis substantial evidence base; Gerhardt 2001 Crohn's evidence. Reasonable adjunct to established IBD therapy under gastroenterology coordination. Substantial pharmacological mechanism through 5-LOX inhibition affecting inflammatory bowel disease pathophysiology.

• Asthma adjunctive (mechanistic rationale)

  Strength of evidence for this group: cautious

  Gupta 1998 substantial pulmonary function evidence; substantial mechanistic rationale through 5-LOX inhibition affecting leukotriene synthesis. Reasonable adjunct to established asthma therapy under pulmonology coordination. Not substitute for inhaled corticosteroids, bronchodilators, or leukotriene receptor antagonists (montelukast).

• Chronic inflammatory conditions general

  Strength of evidence for this group: modest

  Reasonable supplementation framework for general inflammatory condition supplementation alongside established medical management. Substantial mechanistic rationale through 5-LOX inhibition complementing NSAID COX inhibition.

• Combination with curcumin / NSAID combination therapy

  Strength of evidence for this group: modest

  Substantial mechanistically complementary combination with curcumin (NF-κB, COX-2 inhibition) and modestly complementary with NSAIDs (COX inhibition vs boswellia 5-LOX). Reasonable comprehensive anti-inflammatory framework.

• Pregnancy and lactation

  Strength of evidence for this group: cautious

  Limited modern therapeutic supplementation safety data; substantial traditional Ayurvedic and Middle Eastern medicinal heritage. Modern therapeutic supplementation generally avoided during pregnancy without specialist coordination; specialist Ayurvedic practitioners may have substantial traditional use frameworks.

• Pediatric use

  Strength of evidence for this group: cautious

  Limited pediatric therapeutic supplementation framework. Specialist coordination essential if pediatric supplementation considered. Substantial Ayurvedic heritage includes pediatric traditional use frameworks; modern therapeutic supplementation more cautious approach.

• Anticoagulant users

  Strength of evidence for this group: cautious

  Modest theoretical antiplatelet effects; substantial less interaction profile than curcumin. Coordinate with anticoagulation management; routine INR monitoring reasonable.

• Surgical patients (pre-operative)

  Strength of evidence for this group: cautious

  Modest antiplatelet effects warrant routine pre-operative supplement review. Less substantial bleeding risk than curcumin; reasonable to discontinue 1 week before scheduled surgery.

• Diabetes management

  Strength of evidence for this group: cautious

  Modest glucose-modulating effects; substantial monitoring reasonable for diabetes patients. Coordinate with endocrinology for diabetic patients on insulin or sulfonylureas.

• Healthy adults seeking anti-inflammatory supplementation

  Strength of evidence for this group: modest

  Reasonable supplementation framework for healthy adults seeking nutraceutical anti-inflammatory support alongside anti-inflammatory dietary patterns and lifestyle factors.

• Curcumin (Combination Therapy)

  Interaction: synergy

  Substantial mechanistically complementary combination, curcumin acts through NF-κB and COX-2 inhibition; boswellia acts through 5-LOX inhibition. Substantial dual-pathway anti-inflammatory mechanism. Substantial commercial combination products (Curamin from Terry Naturally, Curamed combinations, various others). Among the most substantial nutraceutical anti-inflammatory combinations.

• NSAIDs (Ibuprofen, Naproxen, Celecoxib)

  Interaction: synergy

  Substantial mechanistically complementary combination, NSAIDs act through COX inhibition; boswellia acts through 5-LOX inhibition. Reasonable combination for inflammatory conditions; substantial dual-pathway anti-inflammatory framework. Modest combined antiplatelet considerations.

• Glucosamine / Chondroitin / MSM

  Interaction: synergy

  Substantial joint health combination, boswellia provides anti-inflammatory mechanism; glucosamine/chondroitin/MSM provide substantial joint structural support. Reasonable comprehensive joint health framework.

• Omega-3 Fatty Acids

  Interaction: synergy

  Substantial mechanistically complementary combination, omega-3s provide substrate for anti-inflammatory eicosanoids; boswellia inhibits 5-LOX pathway leukotriene synthesis. Substantial dual-mechanism anti-inflammatory framework.

• Vitamin D3

  Interaction: synergy

  Reasonable bone-joint inflammation framework, vitamin D3 modulates immune function and bone metabolism; boswellia provides complementary anti-inflammatory mechanism. Reasonable combination for arthritis and inflammatory bone disease applications.

• Mesalamine / Sulfasalazine (IBD)

  Interaction: synergy

  Substantial Madisch 2007 evidence demonstrating boswellia H15 comparable to mesalamine in UC maintenance. Reasonable adjunct to established IBD therapy under gastroenterology coordination.

• Asthma Controller Medications (Montelukast, Inhaled Corticosteroids)

  Interaction: synergy

  Substantial mechanistic rationale through 5-LOX inhibition affecting leukotriene synthesis, complementary to montelukast (leukotriene receptor antagonism) and inhaled corticosteroids. Reasonable adjunct under pulmonology coordination.

• Anticoagulants (Warfarin, DOACs, Antiplatelets)

  Interaction: caution

  Modest theoretical antiplatelet effects; substantially less interaction profile than curcumin. Coordinate with anticoagulation management; routine INR monitoring reasonable for warfarin patients.

• Diabetes Medications

  Interaction: caution

  Modest glucose-modulating effects; substantial monitoring reasonable for diabetes patients on insulin or sulfonylureas. Coordinate with endocrinology.

• Immunosuppressants

  Interaction: caution

  Substantial 5-LOX inhibition may modestly affect immune function; specialist coordination for transplant medicine or autoimmune disease patients on immunosuppressant therapy.

• Pregnancy and Lactation

  Interaction: caution

  Limited modern safety data; substantial Ayurvedic heritage includes pregnancy use frameworks; modern therapeutic supplementation generally avoided without specialist coordination.

• Surgical Patients (Pre-operative)

  Interaction: caution

  Modest antiplatelet effects; discontinue 1 week before scheduled surgery to minimize bleeding risk.

Look for: AKBA standardization disclosure (5-Loxin 30% AKBA being substantial benchmark; Aflapin enhanced bioavailability AKBA framework); specific commercial formulation identification (5-Loxin, Aflapin, Apres Flex trademark verification); appropriate dose for intended application; reputable manufacturer with substantial commercial heritage; third-party testing for heavy metal contamination; GMP certification disclosure; substantial Boswellia serrata species identification (vs Boswellia sacra essential oil for aromatherapy). Avoid: non-standardized boswellia extracts when clinical outcomes desired; products without specific AKBA content disclosure; products from sources without sustainability sourcing framework given substantial conservation concerns; products with substantial undisclosed proprietary blend frameworks; reliance on Boswellia essential oil (frankincense oil) for therapeutic supplementation applications (substantial pharmacology distinction).

Boswellia (Indian frankincense, Salai guggal in Sanskrit) has substantial documented use in Ayurvedic medicine across multiple millennia, substantial heritage for arthritis, asthma, inflammatory conditions, and digestive disorders. The substantial Ayurvedic framework includes substantial diverse formulation approaches (resin chewing, powders, decoctions, oils) across substantial therapeutic applications. The substantial cultural significance extends across Hindu and Buddhist religious frameworks with substantial ceremonial integration. The substantial Middle Eastern frankincense heritage centers on Boswellia sacra (Arabian frankincense) and Boswellia carteri (substantial historical religious use across Christianity, Judaism, Islam). The substantial Frankincense Trail (substantial trade route across Arabian peninsula through Yemen, Oman, and broader Middle East) provided substantial economic infrastructure across multiple centuries. Pliny the Elder, Hippocrates, Theophrastus, and various other classical writers documented substantial medicinal use frameworks. The substantial European pharmaceutical research era developed substantially through 1980s-2000s. The substantial German pharmaceutical research framework through Sander 1998 substantial chronic polyarthritis evaluation and Gerhardt 2001 Crohn's evidence base supported substantial European clinical research investment. The substantial H15 extract framework (substantial German pharmaceutical development) provided foundational clinical evidence base for inflammatory bowel disease applications. The substantial mechanistic characterization era centered on Safayhi 1992 substantial 5-lipoxygenase inhibition foundational research. The substantial mechanistic framework established 5-LOX inhibition as primary boswellia anti-inflammatory mechanism distinct from NSAID COX inhibition, substantial mechanistic distinctness providing reasonable framework for combination supplementation with NSAID therapy. The substantial commercial AKBA standardization era developed substantially through 2000s-2010s. 5-Loxin commercial development by Sabinsa (Muhammed Majeed company) provided foundational AKBA standardization commercial framework. Sengupta 2008 Arthritis Res Ther 5-Loxin osteoarthritis RCT provided foundational clinical evidence for standardized formulation framework. Substantial subsequent commercial expansion through Aflapin (enhanced bioavailability), Apres Flex (water-soluble), Boswellin Super (broader boswellic acid spectrum), and various other commercial formulations. The substantial combination product era developed substantially through 2000s-2020s. Substantial curcumin-boswellia combination products (Curamin from Terry Naturally, Curamed combinations, broader category) leveraged substantial mechanistic complementarity between curcumin (NF-κB, COX-2 inhibition) and boswellia (5-LOX inhibition), among the most substantial nutraceutical anti-inflammatory combinations. The modern boswellia landscape continues substantial expansion through 2020s with substantial supplement industry commercial framework, substantial ongoing research investment across osteoarthritis, rheumatoid arthritis, inflammatory bowel disease, asthma, and other applications, substantial sustainability conservation framework development given Boswellia tree resource concerns, substantial regulatory framework development, and substantial consumer market education. The substantial M-07 Form-Factor flag content remains foundational, AKBA-standardized formulations matter substantially for clinical outcomes versus conventional boswellia extracts.

1. AncientSubstantial Ayurvedic use of Boswellia serrata (Salai guggal) across multiple millennia
2. AncientSubstantial Middle Eastern frankincense (Boswellia sacra, carteri) religious and medicinal use; Frankincense Trail economic infrastructure
3. 1992Safayhi 5-lipoxygenase inhibition foundational mechanism characterization
4. 1996Etzel chronic polyarthritis evaluation
5. 1998Sander rheumatoid arthritis pilot; Gupta asthma RCT
6. 2001Gerhardt Crohn's disease RCT
7. 2003Kimmatkar osteoarthritis RCT
8. 2006Ammon substantial mechanistic and clinical review
9. 2007Madisch ulcerative colitis substantial RCT (H15 comparable to mesalamine)
10. 2008Sengupta 5-Loxin osteoarthritis RCT; Roy mechanism characterization
11. 2010sAflapin enhanced bioavailability commercial development
12. 2011Vishal Aflapin OA enhanced bioavailability evidence
13. 2018Bannuru osteoarthritis meta-analysis substantial synthesis
14. 2020sSubstantial combination product expansion (Curamin, Curamed framework); substantial sustainability conservation framework development

• Whether substantial AKBA-standardized formulations produce clinically meaningful advantages over conventional boswellia extracts across the range of inflammatory conditions or whether substantial benefit is limited to specific applications.
• Whether emerging enhanced bioavailability formulations (Aflapin polysaccharide carrier, Apres Flex water-soluble, others) will produce substantially different clinical outcomes than 5-Loxin AKBA standardization framework.
• Whether substantial boswellia inflammatory bowel disease evidence (Madisch 2007 UC, Gerhardt 2001 Crohn's) will mature into established complementary IBD therapy framework versus remaining traditional medicine framework.
• Whether substantial boswellia asthma evidence (Gupta 1998 substantial pulmonary function evidence) will mature into established complementary asthma therapy framework.
• Whether substantial boswellia cancer applications (preliminary preclinical evidence across multiple cancer types including glioma, breast, colorectal) will mature into oncology adjunctive framework.
• Whether substantial Ayurvedic heritage framework will substantially influence Western boswellia supplementation patterns versus remaining distinct traditional medicine framework.
• How substantial Boswellia serrata vs Boswellia carteri vs other species comparative pharmacology will mature, different species have substantially different boswellic acid profiles.
• Whether substantial sustainability concerns about Boswellia tree resource conservation (substantial deforestation and overharvesting concerns in some regions) will produce substantial supply chain changes.

Widely available globally through direct-to-consumer retailers, Amazon, GNC, Vitamin Shoppe, mass-market pharmacies (CVS, Walgreens), specialty supplement retailers, and substantial Ayurvedic and Indian grocery suppliers (whole resin and powder forms). Legal under DSHEA in the United States and equivalent supplement regulations in most jurisdictions. Not on WADA prohibited list. Substantial pricing variation by formulation: standard boswellia extract $10-20/month at typical dosing; 5-Loxin products $25-40/month; Aflapin products $30-45/month; Apres Flex products $25-40/month; H15 extract products $50-80/month; curcumin-boswellia combination products $30-60/month. Substantial Indian manufacturer infrastructure through Sabinsa (Muhammed Majeed company, substantial 5-Loxin, Aflapin, Boswellin Super development), Laila Nutraceuticals (Apres Flex), and substantial broader Indian botanical industry. Substantial European pharmaceutical heritage through H15 extract (substantial German pharmaceutical development for inflammatory bowel disease applications). Substantial US distribution through Terry Naturally (Curamin combination), Solgar, Now Foods, Pure Encapsulations, Designs for Health, Life Extension, Thorne Research, Solaray, and substantial broader supplement industry framework. Substantial Ayurvedic medicine framework through traditional Indian practitioners and substantial cultural integration. Substantial Middle Eastern traditional medicine framework through traditional Arabian practitioners. Substantial historical religious and ceremonial use across Christianity (frankincense in liturgy), Judaism (frankincense in Temple service), Islam (substantial historical and contemporary use). Quality verification through USP, NSF, ConsumerLab third-party testing where available. Travel availability excellent given substantial global supplement industry distribution.

Status current as of July 2026. Regulatory positions change, sometimes quickly.

Class

Class B, traditional herb-derived resin extract

Primary species

Boswellia serrata (Indian frankincense)

Active compounds

Boswellic acids; AKBA (acetyl-11-keto-β-boswellic acid) primary

Mechanism

5-lipoxygenase (5-LOX) inhibition (distinct from NSAID COX)

Foundational study

Safayhi 1992 5-LOX mechanism; Sengupta 2008 5-Loxin OA RCT

Major commercial formulations

5-Loxin (Sabinsa 30% AKBA), Aflapin (enhanced bioavailability), Apres Flex (water-soluble)

What follows is unfinished work on our side, not a finding about Boswellia. A short entry is not a safe entry.

• Cost and market. We have not documented what it sells for or who sells it.
• Supply chain. We have not mapped where it is made.
• Who uses it. We have not documented the user groups.
• What could change. No forward-looking summary yet.
• How it compares. We have not set it against the alternatives.
• Children and teenagers. We have not checked what is known about younger people.
• Where we land. We have not taken a position on this yet.